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Abstract 
Background: Malaria caused by Plasmodium falciparum is the most virulent form of malaria, leading to approxi-
mately a half million deaths per year. Chemotherapy continues to be a key approach in malaria prevention and treat-
ment. Due to widespread parasite drug resistance, identification and development of new anti-malarial compounds 
remains an important task of malarial parasitology. The semi-synthetic drug amitozyn, obtained through alkylation of 
major celandine (Chelidonium majus) alkaloids with N,N′N′-triethylenethiophosphoramide (ThioTEPA), is a widely used 
Eastern European folk medicine for the treatment of various tumours. However, its anti-malarial effect has never been 
studied.
Methods: The anti-malarial effects of amitozyn alone and in combination with chloroquine, pyrimethamine and arte-
misinin on the blood stages of P. falciparum were analysed. The cytostatic effects of amitozyn on parasites and various 
cancerous and non-cancerous human cells were compared and their toxic effects on unparasitized human red blood 
cells were analysed.
Results: Obtained results demonstrate that amitozyn effectively inhibits the growth of blood-stage parasites with 
IC50 9.6 ± 2, 11.3 ± 2.8 and 10.8 ± 1.8 μg/mL using CS2, 3G8 and NF54 parasite lines, respectively. The median IC50 for 
14 tested human cell lines was 33–152 μg/mL. Treatment of uninfected red blood cells with a high dose of amitozyn 
(500 μg/mL) did not change cell morphology, demonstrating its non-toxicity for erythrocytes. The synergistic impact 
of the amitozyn/chloroquine combination was observed at growth inhibition levels of 10–80 %, while demonstrating 
a nearly additive effect at a growth inhibition level of 90 %. The combination of amitozyn with pyrimethamine has 
a synergistic effect at growth inhibition levels of 10–70 % and a nearly additive effect at a growth inhibition level of 
90 %. The synergistic anti-malarial effect of the amitozyn/artemisinin combination was observed at growth inhibition 
levels of 10–40 % and a nearly additive effect at growth inhibition levels of 50–90 %.
Conclusions: These in vitro results suggest that the semi-synthetic drug amitozyn, typically used for the treatment of 
tumours, is a potential anti-malarial candidate and warrants more detailed laboratory and pre-clinical investigations.
Keywords: Malaria, Amitozyn, Alkaloids, Microtubules, Isobolographic analysis
© 2015 Tcherniuk et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
In humans, malaria is caused by five species: Plasmo-
dium falciparum, Plasmodium malariae, Plasmodium 
ovale, Plasmodium vivax, and Plasmodium knowlesi 
[1, 2]. Among infected individuals, P. falciparum is the 
most common species identified (about 75  %) followed 
by P. vivax (about 20  %) [3]. Moreover, P. falciparum 
represents the most virulent form of human malaria, 
causing the majority of deaths [4] although it has been 
shown recently that malaria induced by P. vivax may also 
be associated with potentially life-threatening conditions 
[5].
The first known anti-malarial treatment was infusion 
of bark obtained from plants of the Cinchona genus [6]. 
Its anti-malarial activity was attributed to the alkaloid 
quinine (QN), which was characterized in 1820 and used 
as the anti-malarial compound for extended periods of 
time. Later the QN was replaced by chloroquine (CQ)—a 
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cheaper, synthetic analogue. Appearance of CQ-resistant 
strains led to the discovery of the new potent anti-malar-
ial drug artemisinin (ART) in the 1970s. This natural ses-
quiterpene endoperoxide is currently one of the major 
anti-malarial drugs used around the world. However, P. 
falciparum resistance to ART and its derivatives has been 
described recently [7]. At present ART derivatives are 
commonly used in drug combinations with lumefantrine, 
amodiaquine, mefloquine, sulfadoxine-pyrimethamine 
and antibiotics to treat uncomplicated P. falciparum 
malaria and P. vivax in areas of CQ resistance [8, 9].
There is a large arsenal of synthetic and natural com-
pounds possessing anti-malarial activity. These com-
pounds belong to different chemical classes and have 
different mechanisms of action. It is already known that 
some anticancer drugs have strong anti-malarial effect. 
For example, antimetabolite methotrexate [10], paclitaxel 
[11], vinblastine [12], cisplatin [13], and bortezomib [14] 
demonstrate potent activity against the blood stages of P. 
falciparum.
In this work, the antiparasitic effect of the semi-
synthetic drug amitozyn was studied. Obtained results 
demonstrate that amitozyn possesses anti-malarial 
activity and inhibits in  vitro blood stage growth of P. 
falciparum. Earlier, it has been shown that amitozyn 
is an effective anticancer drug, which acts as a micro-
tubule modulator [15]. In this work the microtubule 
depolymerization effect of amitozyn was observed at 
different blood stages of P. falciparum, which could be 
the principal cause of its anti-malarial effect. Combina-
tion of amitozyn with CQ showed a synergistic anti-
malarial effect at growth inhibition levels of 10–80  % 
and a nearly additive effect at a growth inhibition level 
of 90  %. Amitozyn/pyrimethamine combinations pro-
voked a synergistic anti-malarial effect at growth inhi-
bition levels of 10–70 % and a nearly additive effect at 
growth inhibition levels of 80–90  %. Amitozyn/arte-
misinin combinations showed a synergistic anti-malar-
ial effect at growth inhibition levels of 10–40  % and a 




The semi-synthetic drug amitozyn was prepared as 
described previously at a concentration of 25  mg/mL 
[15]. CQ, pyrimethamine, ART, monoclonal mouse anti-
α-tubuline (T9026), and polyclonal anti-γ-tubuline anti-
bodies (T3559) were purchased from Sigma. Advanced 
RPMI Medium 1640, Alexa Fluor 488 goat anti-mouse 
and Alexa Fluor 594 goat anti-rabbit antibodies were 
from Invitrogen. 4′,6-Diamidino-2-phenylindole, 
dihydrochloride (DAPI) and LDH cytotoxicity kit were 
from Termo Scientific Pierce. EGM-2 medium was from 
Lonza. The polyclonal rabbit anti-human RBC antibodies 
were from Rockland. Human blood O+ and AB human 
serum were purchased from Valley Biomedical.
Human HeLa, KB3, HT29, HCT116, A549, IMR90, 
HUVEC, MESSA, and murine B16, GL26 and COS7 cell 
lines were purchased from ATCC. HCT116 p53(−/−) 
cells with homozygous knock-out of p53 were kindly pro-
vided by Dr D Skoufias (IBS, Grenoble, France). Taxol-
resistant A549T12 cells were obtained with permission 
from Dr S Horwitz (Albert Einstein College of Medicine, 
New York, NY, USA). The MESSA Dx5 cells were kindly 
provided by Dr L Lafanechère (CNRS, UMR 5168/CEA/
IRTSV, Grenoble, France).
Ethics statement
Ethics approval was obtained from the Florida Atlan-
tic University Institutional Review Board committee for 
using human erythrocytes for culturing malaria para-
sites. Blood was provided by Valley Biomedical.
Parasite culture
CS2, NF54 and 3G8 (kindly provided by Dr J Smith) 
strains of P. falciparum, were grown in human O+ eryth-
rocytes at 2  % haematocrit in complete medium con-
taining RPMI 1640 supplemented with 10  % human 
serum and 40  μg/mL gentamicin sulphate as previously 
described [16]. Cultures were maintained at 37 °C in a gas 
mixture of 5 % CO2, 5 % O2 and 90 % N2. Synchronization 
was performed using 5 % d-sorbitol [16].
In vitro drug susceptibility assays
The antiparasitic effects of amitozyn, CQ, pyrimeth-
amine and ART were tested on the CS2, 3G8 and NF54 
strains of P. falciparum by counting infected erythro-
cytes visualized by a standard Giemsa staining method 
[17]. The combinatory effect of amitozyn/chloroquine, 
amitozyn/pyrimethamine and amitozyn/artemisinin was 
analysed using the same method in the 3G8 strain. Non-
synchronized parasites (0.5 %) with 2 % haematocrit were 
seeded in a 96-well plate and amitozyn (0–125  μg/mL), 
CQ (0–30  nM), pyrimethamine (0–20  nM), and ART 
(0–4 nM) were added to the media. Plates were incubated 
at 37 °C for 96 h with periodic change of media (contain-
ing appropriate drug concentration) every 24  h. DMSO 
(0.1  %) was used as a control. Parasitaemia was deter-
mined by light microscopy after Giemsa staining at time 
points of 24, 48, 72, and 96 h. Antiparasitic effect (APE) 
of drugs was measured in per cent and calculated by the 
equation APE (%) = 100 − RP, where RP is a per cent of 
parasitaemia relative to control (no drug).
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Cell viability and cytotoxicity assay
The antiproliferative effect of amitozyn was analysed in 
14 different cell lines. HeLa, IMR90, GL26, COS7, and 
B16 cells were grown in DMEM medium supplemented 
with 2  mM  l-glutamine, 1  % penicillin/streptomycin 
and 10 % FBS. KB cells were grown in the same medium 
supplemented with 20  % FBS. MESSA, MESSA (Dx5) 
MDR, A549, and A549T12 were cultivated in RPMI 1640 
medium supplemented with 2  mM  l-glutamine, 1  % 
penicillin/streptomycin and 10  % FBS. The medium for 
A549T12 cells was additionally supplemented with 2 nM 
paclitaxel. HCT 116, HCT 116 p53(−/−), and HT29 
were cultivated in McCoy’s 5A medium supplemented 
with 1 % penicillin/streptomycin and 10 % FBS. HUVEC 
were grown in EGM-2 medium supplemented with 2  % 
FBS. All cell lines were maintained in a humid incubator 
at 37 °C in 5 % CO2.
To estimate the antiproliferative effect of amitozyn 
in human cells, the crystal violet cell viability assay was 
performed. Aliquots of 4–6 × 103 cells/well were seeded 
in 96-well plates and incubated with 0–500  μg/mL of 
amitozyn, for 72  h. The cells were washed with PBS, 
fixed with formaldehyde (3.7 %) for 30 min, and stained 
with 0.1 % crystal violet for 10 min, washed abundantly 
with water, and dried at room temperature. Finally, a 
10  % solution of acetic acid was added to each sample 
to dissolve the blue dye. The absorbance of the sam-
ples was measured spectrophotometrically at 595  nm 
for quantitative evaluation of cell viability. Cell viability 
was calculated by the following equation: Cell viabil-
ity (%) = Q(Dr)/Q(ctrl) ×  100, where Q(Dr) is quantity 
of viable cells after appropriate drug treatment, Q(ctrl) 
is quantity of viable cells in the control. To estimate the 
antiproliferative effect of amitozyn/chloroquine, ami-
tozyn/pyrimethamine and amitozyn/artemisinin com-
binations in the human cells, the HUVEC culture was 
treated with amitozyn (0, 7.5, 15, 30, 60, 125, 250, 500 μg/
mL) combined with above-mentioned drugs at molar 
ratio 1:1 for 72  h. Then the crystal violet cell viability 
assay was performed as described above. Growth inhi-
bition (GI) was calculated by the following equation GI 
(%) = 100 − cell viability (%).
To analyse the cytotoxic effect of amitozyn on red 
blood cells (RBC), RBC (O+) at 2  % haematocrit were 
seeded in 96-well plates and incubated with 0, 30, 60, 
125, 250, 500 μg/mL of amitozyn for 24, 48, 72, and 96 h. 
RBC incubated with complete RPMI supplemented with 
0.1 % Triton X-100 were used as a positive cytotoxic con-
trol. At the desired time point the medium was removed 
and tested in triplicates using the lactate dehydrogenase 
(LDH) cytotoxicity kit. The results of cytotoxicity assay 
were calculated as described in the kit manual. The sta-
tistical significance of the difference between the control 
and treated groups was determined by Student t test. P 
value ≤0.05 was considered to be statistically significant.
Isobolographic analysis
The combination index (CI) of amitozyn/chloro-
quine, amitozyn/pyrimethamine and amitozyn/arte-
misinin combinations was calculated at various levels 
of antiparasitic or growth inhibition effects (from 10 to 
90  %) to evaluate their combination effects in the 3G8 
strain of P. falciparum and in the HUVEC, respectively, 
as was described earlier [18]. CI was calculated by the 
equation CIx  =  (DA/(Dx)A)  +  (DB/(Dx)B)  +  (DA  ×  DB)/
((Dx)A  ×  (Dx)B) for a mutually non-exclusive interac-
tion, where DA is a dose of amitozyn used in combina-
tion with drug B (CQ, pyrimethamine or ART) required 
for the effect of X  %, (Dx)A is a dose of amitozyn alone 
required for the effect of X %, DB is a dose of drug B (CQ, 
pyrimethamine or ART) used in combination with ami-
tozyn required for the effect of X % and (Dx)B is a dose 
of drug B (CQ, pyrimethamine or ART) alone required 
for the effect of X  %. The synergistic, nearly additive or 
antagonistic effect was determined by the scale described 
earlier [19]. CI values from 0.9 up to 1.1 indicated nearly 
additive effect and CI values less than 0.9 indicated syn-
ergistic effects. All experiments were repeated at least 
three times.
Immunofluorescence
To analyse the effect of amitozyn on the parasite micro-
tubules, the RBC (2  % haematocrit) were infected with 
the 3G8 strain of P. falciparum. At 2 % parasitaemia the 
infected RBC were treated with amitozyn (0–250 μg/mL) 
for 24 h. Treated and untreated RBC were harvested and 
fixed by 4 % paraformaldehyde in PBS supplemented with 
0.0075 % glutaraldehyde for 30 min at 37 °C [20]. After a 
few washes in PBS (1 mL), RBC were treated with anti-
human RBC and anti α-tubulin antibodies (Abs) diluted 
1:500 and 1:50, respectively, in the antibody buffer (PBS 
containing 3  % BSA, 0.05  % Tween and 0.02  % sodium 
azide) for 1 h at 37 °C.
Cells were subsequently stained with Alexa Fluor 488 
and Alexa Fluor 594-conjugated goat anti-mouse and 
anti-rabbit secondary Abs at 1:500 dilution for 45  min 
at 37  °C. Finally, cells were counterstained with 1  μg/
mL DAPI. Images were captured by LSM-510 META 
Zeiss confocal microscope and analysed using the ImageJ 
software.
Results
Amitozyn inhibits the growth of Plasmodium falciparum 
cultures in vitro
The susceptibility assay in vitro was performed against P. 
falciparum (CS2, 3G8 and NF 54 parasite lines) in order 
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to analyse the antiparasitic effect of amitozyn. Amitozyn 
treatment inhibited the proliferation of SC2, 3G8 and 
NF54 lines in a dose-dependent manner (Fig.  1a). Cal-
culated IC50 for CS2, 3G8 and NF54 lines were 9.6 ±  2, 
11.3  ±  2.8 and 10.8  ±  1.8  μg/mL respectively (Fig.  1a). 
Treatment with 30  μg/mL amitozyn for 96  h completely 
inhibited the growth of the three parasite lines used 
(Fig.  1a). Pretreatment of P. falciparum (3G8 strain) 
with 15  μg/mL amitozyn for 24  h inhibited the parasite 
growth even after abundant wash and release in drug-free 
medium for 144  h (Additional file  1). Pretreatment with 
the same concentration of amitozyn for 48  h drastically 
inhibited the P. falciparum growth in drug free medium 
but did not diminish the initial parasitaemia. Pretreat-
ment of parasite culture with increased amitozyn con-
centration (30  μg/mL) for 24  h completely inhibited the 
parasite growth in the drug-free medium but similarly did 
not decrease the initial parasitaemia. However, pretreat-
ment with amitozyn 30 μg/mL for 48 h diminished the ini-
tial parasitaemia during release in the drug-free medium 
for 144 h (Additional file 1). These results show that the 
type of antiparasitic effect (cytostatic or cytotoxic) of 
amitozyn depends on the drug concentration and length 
of treatment. It appears that amitozyn used in concentra-
tions up to 15 μg/mL provoked a cytostatic effect, but at 
concentrations of 30 μg/mL amitozyn induced a cytostatic 
or cytotoxic effect depending on the length of treatment.
Importantly, all P. falciparum lines described above 
were significantly more susceptible to amitozyn than the 
wide spectrum of human and mouse cells (Fig. 1b). IC50 
of amitozyn varied from 33 ± 3 μg/mL for HeLa cells up 
to 153 ± 8 μg/mL for HUVEC. These results suggest that 
amitozyn inhibits the proliferation of blood stage P. falci-
parum more effectively than proliferation of the human 
and animal cells.
Amitozyn disrupts the microtubules of Plasmodium 
falciparum
To analyse the effect of amitozyn on the microtubules 
of P. falciparum, amitozyn treated and untreated (con-
trol) RBC infected with P. falciparum (3G8 strain) were 
stained with anti-α-tubuline antibodies. The treatment 
of P. falciparum with 30 μg/mL amitozyn destroyed the 
filamentous structure of parasite microtubules at the ring 
and trophozoite stages (Fig. 2a, b). Importantly, the same 
amitozyn concentration (30 μg/mL) did not induce depo-
lymerization of the metaphase and interphase microtu-
bules in human A549 cells and did not lead to centrosome 
multiplication (Fig. 3). Obtained results demonstrate that 
amitozyn disrupts the microtubule organization in P. fal-
ciparum substantially more effectively than in mamma-
lian cells. It is likely that microtubule depolymerization 
can be one of the major causes of its antiparasitic effect.
Amitozyn halts Plasmodium falciparum development 
at trophozoite stage
To analyse whether amitozyn treatment affects a specific 
stage of parasite development, the changes in the ratio 
of rings, trophozoites and schizonts in the culture of P. 
falciparum (3G8) synchronized at the ring stage were 
measured. Treatment of synchronized P. falciparum 
with 0–30 μg/mL amitozyn did not change the profile of 
normal stage distribution of parasites (Fig. 4). However, 
after treatment with higher (60–125  μg/mL) amitozyn 
concentrations accumulation of trophozoites was clearly 
observed at time points of 48, 72 and 96 h (Fig. 4).
These results suggest that treatment of P. falciparum 
with high amitozyn concentrations halts the parasite cell 
cycle and leads to accumulation of the trophozoite stage.
Fig. 1 Antiproliferative effect of amitozyn on eukaryotic cells and 
culture of Plasmodium falciparum. a IC50 of amitozyn for CS2, 3G8 and 
NF 54 strains of P. falciparum. Human RBC at 2 % haematocrit were 
infected with CS2, 3G8 and NF54 strains of P. falciparum. At 0.5 % 
parasitaemia infected RBC were treated with 0–125 μg/mL amitozyn 
for 96 h and then stained by Giemsa’s method. Parasitaemia was 
analysed by inverted light microscope as described in “Methods”. The 
data were statistically treated and plotted on the graphs using Grah-
Pad software. IC50 values were found from the graph. b Comparison 
of IC50 of amitozyn in eukaryotic cell cultures and in the culture of P. 
falciparum (CS2, 3G8 and NF54 lines). Eukaryotic cells were exposed 
to 0–500 μg/mL amitozyn. At 72 h cells were fixed with 3.7 % formal-
dehyde and stained with 0.1 % crystal violet. Ratio of viable cells was 
analysed as described in “Methods”. The value of IC50 was estimated 
from cell viability plots and presents the average value of the three 
independent experiments
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Amitozyn is not cytotoxic for human red blood cells
To estimate the toxic effects of amitozyn on human RBC, 
freshly prepared RBC (O+) were treated with amitozyn 
(0–500 μg/mL) for 24, 48, 72, and 96 h and analysed for 
the concentration of released LDH. RBC treated with 
complete RPMI media supplemented with 0.1  % Triton 
X-100 were used as a positive control.
Obtained results show that treatment of RBC with 
high doses of amitozyn (30–500 μg/mL) for 96 h did not 
increase the level of released LDH (Fig.  5), showing its 
low toxicity for RBC.
These results demonstrate that the semi-synthetic drug 
amitozyn is not toxic for human RBC and does not pro-
voke haemolysis.
Amitozyn enhances the antiparasitic effects 
of chloroquine, pyrimethamine and artemisinin
To estimate the combinatory effects of amitozyn with 
CQ, pyrimethamine and ART isobolographic analyses 
were performed.
Synergistic effect of amitozyn/chloroquine was 
observed at APE of 10–80 % and a nearly additive effect 
was observed at APE of 90  % (Fig.  6a; Additional files 
2, 3). Combination of amitozyn with pyrimethamine 
provoked a synergistic anti-malarial effect at APE of 
10–70  % and a nearly additive effect at APE of 90  % 
(Fig. 6b; Additional files 2, 3) Combination of amitozyn 
with ART provoked a synergistic anti-malarial effect at 
APE of 10–40  % and a nearly additive effect at APE of 
Fig. 2 Effect of amitozyn on the microtubules of Plasmodium falciparum. Human RBC at 2 % haematocrit were infected with 3G8 strain of P. falci-
parum. At 0.5 % parasitaemia infected RBC (iRBC) were treated with 30 μg/mL amitozyn for 24 h. Untreated iRBC were used as a control. Fixed iRBC 
were stained with anti-α-tubulin (green), anti-RBC (red) and DAPI (blue) and analysed by confocal microscopy. a Rings and b trophozoite stages of P. 
falciparum, respectively
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50–90 % (Fig. 6c; Additional files 2, 3). Furthermore, the 
dose reduction index (DRI) for each drug in their combi-
nation was determined. Combination of amitozyn with 
CQ in the molar ratio 778:1 reduces the effective dose 
of amitozyn from about three to eight times depending 
on the APE (Additional file  4). In contrast, the combi-
nation of CQ with amitozyn in the molar ratio 1:778 
decreased its effective dose about two times for APE of 
10–90  % (Additional file  4). Combination of amitozyn 
with pyrimethamine in the molar ratio 778:1 reduced the 
amitozyn dose three to four times, however, the com-
bination of pyrimethamine with amitozyn in the molar 
ratio 1:778 reduced the pyrimethamine dose from two 
to 44 times depending on the level of APE (Additional 
file  5). More modest DRI was observed for the combi-
nation of amitozyn with ART. The combination of ami-
tozyn with ART in the molar ratio 11,679:1 reduced the 
effective dose of amitozyn two to three times and the 
combination of ART with amitozyn in the molar ratio 
1:11,679 reduced the effective dose of ART four times 
(Additional file  6). The combinatory effect of amitozyn 
with pyrimethamine has a more strong synergistic effect 
compared to the combinatory effect of amitozyn with 
CQ or ART.
The antiproliferative combinatory effects of ami-
tozyn paired with CQ, pyrimethamine and ART on 
the human endothelial cells were also tested (HUVEC, 
Additional file 7). The combination of amitozyn with 
CQ or pyrimethamine at a molar ratio 1:1 has an addi-
tive antiproliferative effect on the HUVEC at all levels 
of growth inhibition. The combination of amitozyn 
with ART at a molar ratio 1:1 has an additive antipro-
liferative effect at growth inhibition levels of 10–70 % 
and slightly antagonistic antiproliferative effect at 
growth inhibition levels of 80–90 % (Additional file 8).
These results suggest that combinations of amitozyn/
chloroquine, amitozyn/pyrimethamine and amitozyn/
artemisinin cause synergistic and nearly additive anti-
malarial effects in the culture of P. falciparum and an 
additive or slightly antagonistic, antiproliferative effect 
on the human cells.
Discussion
For the first time, the anti-malarial effect of the semi-
synthetic anticancer drug amitozyn has been described. 
It was shown earlier that this drug demonstrates anti-
cancer activity in different models and acts by the modu-
lation of microtubule polymerization [15, 21]. The main 
mechanism of amitozyn action in mammalian cells is 
the perturbation of the mitotic spindle, which leads to 
mitotic checkpoint activation, mitotic arrest and apop-
tosis [15]. Similar antimicrotubule effects of amitozyn 
were observed in the P. falciparum parasite. The micro-
tubules of P. falciparum contribute to its shape and 
integrity, and may be involved in motility and invasion 
of the parasite [22, 23]. Moreover, spindle microtubules 
are re-organized into structures that appear to facilitate 
the partition of daughter cells and their organelles dur-
ing parasite development in erythrocytes [24]. It was 
demonstrated that amitozyn depolymerizes the micro-
tubules of the Plasmodium parasite at intra-erythrocytic 
stages (Fig.  2) and leads to post-ring stage accumula-
tion (Fig.  4). Importantly, the antimicrotubule effect of 
amitozyn in the culture of P. falciparum is evident at 
substantially lower concentrations than in the culture 
of mammalian cells. For example, amitozyn depolym-
erizes the parasite microtubules at 30  μg/mL but does 
not induce any visible effect at the same concentration 
in the culture of the lung adenocarcinoma A549 (Fig. 3). 
It is likely that the sensitivity of parasite microtubules to 
amitozyn is a result of different affinities of this drug to 
human and parasitic tubulin due the minor sequence dif-
ferences between tubulins [25–28]. A stronger sensitivity 
of tubulin depolymerization may result in a more potent 
anti-malarial effect. Obtained results demonstrate the 
inhibitory coefficient 50  % (IC50) for the CS2, 3G8 and 
NF54 of P. falciparum lines is significantly lower than 
for the mammalian cell lines (Fig.  1b). Relative resist-
ance of mammalian cells to amitozyn varied from three 
(HeLa cells) up to 15 times (HUVEC) compared to P. 
falciparum (Fig.  1b). This is a promising drug feature 
Fig. 3 Effect of amitozyn on the microtubules of human A549 cells. 
A549 cells were treated with 0 or 30 μg/mL amitozyn for 24 h. Cells 
were fixed with 2 % paraformaldehyde, stained with anti-β-tubulin 
(green), anti-γ-tubulin (red) and DAPI (blue) and analysed by confocal 
microscope
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which potentially may allow the application of amitozyn 
for malaria treatment with minimal secondary effects to 
humans. The non-toxicity of amitozyn for RBC, even at 
extremely high concentrations (500 μg/mL), represents a 
supplemental advantageous point of this drug (Fig. 5).
Drug combinations are extensively used in medi-
cal practice to enhance their anti-malarial impact and 
simultaneously decrease their doses. Synergistic or nearly 
additive drug interactions attenuate the secondary effects 
and significantly improve the antiparasite treatment. 
Multiple data describing interactions of the anti-malarial 
drugs in vitro were reported [29–36].
IC50 levels of amitozyn (7.7  μM), CQ (29.4  nM), 
pyrimethamine (6.8  nM), and ART (1.5  nM) were 
Fig. 4 Effect of amitozyn on the parasite developmental stage distribution. Plasmodium falciparum (3G8) culture was synchronized at the ring stage 
using 5 % d-sorbitol. iRBC were treated with 0–125 μg/mL amitozyn for 24, 48, 72, and 96 h and then stained by Giemsa’s method. The relative ratio 
of rings, trophozoites and schizonts was analysed by inverted light microscope as described in “Methods”
Page 8 of 10Tcherniuk et al. Malar J  (2015) 14:425 
significantly diminished when these drugs were used in 
combinations. The combination of amitozyn with CQ 
resulted in a synergistic interaction at a range of APE 
from 10 up to 80 % and a nearly additive effect at APE 
of 90  % (Fig.  6a; Additional files 2, 3). Amitozyn and 
CQ target different physiological mechanisms of par-
asites which are important for its viability. The anti-
malarial effect of CQ results from its accumulation at 
high levels in the acidic lysosomal food vacuole of the 
parasite and its binding to haematin. The food vacuole 
is the site of haemoglobin degradation in the parasite, 
and iron (II) haem is released as a by-product. Under 
normal circumstances, the iron (II) haem is oxidized to 
iron (III) haematin and sequestered into a polymer of 
β-haematin as an inert pigment called hemozoin. CQ 
binds to haematin and disrupts its polymerization. It 
has been demonstrated that free haematin or CQ-hae-
matin complexes are membrane interactive and toxic 
to the parasite [37]. Inhibition of haematin polymeri-
zation together with microtubule disruption during 
intracellular development of the parasite may lead to 
a synergistic anti-malarial effect. Interestingly, the 
synergistic impact of amitozyn/chloroquine combina-
tions was inversely proportional to the growth inhibi-
tion level. The synergistic interaction was observed at 
APE of 10 and 20 %, a moderate synergistic effect was 
observed at APE of 30–60 %, a slight synergistic effect 
was observed at APE of 70–80 %, and a nearly additive 
effect was observed at APE of 90 % (Fig. 6a; Additional 
files 2, 3).
Combinations of amitozyn with pyrimethamine 
induced a pronounced synergistic effect at APE of 
10–60 %, a moderate synergistic effect at APE of 70 % 
and a nearly additive effect at APE of 80 and 90  % 
(Fig.  6b; Additional files 2, 3). As known, pyrimeth-
amine inhibits dihydrofolate reductase (DHFR) from 
the parasite to a greater degree than DHFR from the 
host and thus shows a selective toxicity towards the 
parasite [38]. DHFR is a ubiquitous enzyme that par-
ticipates in the recycling of folates by reducing dihy-
drofolate to tetrahydrofolate [39]. Inhibition of DHFR 
Fig. 5 Cytotoxic effect of amitozyn on human erythrocytes. Human 
erythrocytes (O+) at 2 % haematocrit were treated with 0, 30, 60, 125, 
250, and 500 μg/mL amitozyn or complete RPMI supplemented with 
0.1 % Triton X-100 (positive control) for 24, 48, 72, and 96 h. Cytotoxity 
was determined by LDH kit as described in “Methods”
Fig. 6 Isobolographic analysis of combined effects of amitozyn 
with chloroquine, pyrimethamine and artemisinin in the culture of 
Plasmodium falciparum (3G8). Calculation of CI values of a amitozyn/
chloroquine, b amitozyn/pyrimethamine and c amitozyn/artemisinin 
combinations at antiparasitic effects from 10 to 90 %. Human RBC at 
2 % haematocrit were infected with 3G8 line of P. falciparum. At 0.5 % 
parasitaemia iRBC were treated with amitozyn (0–60 μg/mL), chlo-
roquine (0–30 nM), pyrimethamine (0–20 nM), artemisinin (0–4 nM), 
and the combinations of amitozyn with chloroquine, pyrimethamine 
and artemisinin in the molar ratio 778:1, 778:1 and 11,679:1, respec-
tively, for 96 h. CI was calculated as described in “Methods”
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prevents the formation of fully reduced tetrahydro-
folate, which participates in purine, pyrimidine and 
amino acid biosynthetic pathways [40]. Lower levels of 
tetrahydrofolate decrease the conversion of glycine to 
serine, reduce methionine synthesis and lower thymi-
dylate levels with a subsequent arrest of DNA replica-
tion [41–43]. The toxic effect of pyrimethamine on the 
parasite reaches a peak in the late erythrocytic schiz-
ont stage, precisely when DNA synthesis peaks [44]. 
Simultaneous affection of DNA replication and micro-
tubule integrity may significantly inhibit the parasite 
production and lead to the synergistic anti-malarial 
effect.
The combinations of amitozyn with ART slightly 
enhanced the antiparasitic effect of both drugs. A 
moderate synergistic interaction was observed at 
APE of 10–40  % and a nearly additive effect at APE 
of 50–90  % (Fig.  6c; Additional files 2, 3). The pre-
cise mechanism of ART action is not completely 
clear. It was reported that ART specifically inhibits 
the PfATP6 enzyme, which is essential for oxidative 
metabolism in the parasite [45], but this mechanism 
was questioned later [46]. Another possible mecha-
nism of ART action is the production of carbon-
centred free radicals [47] or production of reactive 
oxygen species within the mitochondria of the malar-
ial parasite [48]. Furthermore, a number of studies 
have shown that ART covalently reacts with several 
parasitic proteins [49]. Combinations of amitozyn 
with ART moderately enhanced the anti-malarial 
effect in contrast to amitozyn/chloroquine and ami-
tozyn/pyrimethamine combinations. Importantly, 
amitozyn combined with CQ, pyrimethamine and 
ART in the culture of HUVEC did not induce the syn-
ergistic antiproliferative effect, in contrast to the cul-
ture of P. falciparum.
Conclusions
The anticancer drug amitozyn effectively inhibits P. fal-
ciparum proliferation in doses significantly lower than 
those inhibiting human cell growth. Moreover, this drug 
is not toxic for RBC and enhances the anti-malarial effect 
of CQ, pyrimethamine and ART in the in vitro culture of 
P. falciparum, but does not enhance the cytostatic effect 
of mentioned drugs in the culture of human cells. All 
these results provide a strong basis for future detailed 
investigations of the anti-malarial effect of amitozyn.
It has been shown for the first time that the semi-syn-
thetic drug amitozyn has anti-malarial properties and 
might be a useful candidate for treatment of malaria, 
induced by P. falciparum, alone or in combinations with 
other anti-malarial drugs.
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Additional file 1. Antiparasitic effect of amitozyn pretreatment. Human 
RBC at 2 % haematocrit were infected with 3G8 strain of P. falciparum. 
At 1 % of parasitaemia iRBC were pretreated with 0, 15 and 30 μg/mL 
amitozyn for 24 or 48 h. After wash (three times) iRBC were diluted to 
parasitaemia 0.5 % and released in the drug-free medium for 144 h. At 
time points 48, 96 and 144 h iRBC were collected and stained by Giemsa’s 
method. Parasitaemia was analysed by inverted light microscope. The 
data were statistically treated and plotted on the graphs using GraphPad 
software. Error bars present the standard deviation.
Additional file 2. Antiparasitic effect of (A) amitozyn/chloroquine 
combinations in the ratio 778:1, (B) chloroquine/amitozyn combinations 
in the ratio 1:778, (C) amitozyn/pyrimethamine combinations in the ratio 
778:1, (D) pyrimethamine/amitozyn combinations in the ratio 1:778, (E) 
amitozyn/artemisinin combinations in the ratio 11,679:1, (F) artemisinin/
amitozyn combinations in the ratio 1:11,679.
Additional file 3. CI values of amitozyn/chloroquine, amitozyn/
pyrimethamine and amitozyn/artemisinin combinations at different levels 
of antiparasitic effect.
Additional file 4. Drug reduction index of amitozyn/chloroquine and 
chloroquine/amitozyn combinations.
Additional file 5. Drug reduction index of amitozyn/pyrimethamine and 
pyrimethamine/amitozyn combinations.
Additional file 6. Drug reduction index of amitozyn/artemisinin and 
artemisinin/amitozyn combinations.
Additional file 7. Antiproliferative effect of amitozyn combinations with 
chloroquine, pyrimethamine and artemisinin on the HUVEC. (A) amitozyn/
chloroquine (B) chloroquine/amitozyn (C) amitozyn/pyrimethamine 
(D) pyrimethamine/amitozyn (E) amitozyn/artemisinin (F) artemisinin/
amitozyn combinations. HUVEC were treated with amitozyn (0-500 μg/
mL), chloroquine (0-200 μM), pyrimethamine (0-160 μM), artemisinin 
(0-160 μM), and the combinations of amitozyn with chloroquine, 
pyrimethamine and artemisinin in the molar ratio 1:1 for 72 h. Then cells 
were fixed with 3.7 % formaldehyde and stained with 0.1 % crystal violet. 
Per cent of growth inhibition was analysed as described in “Methods”.
Additional file 8. Isobolographic analysis of combined effects of ami-
tozyn with chloroquine, pyrimethamine and artemisinin on the HUVEC.
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